Meropenem monotherapy as an empirical treatment of febrile neutropenia in childhood cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 1, 2010, Pages 123-126

  Erbey, Fatih ^a   Bayram, Ibrahim ^a   Yilmaz, Sema ^a   Tanyeli, Atila ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Choldhood cancer; Febrile neutropenia; Meropenem treatment

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; MEROPENEM; THIENAMYCIN DERIVATIVE;

ADOLESCENT; CHEMICALLY INDUCED; CHILD; COMPLICATION; FEMALE; HUMAN; INFANT; MALE; MICROBIOLOGY; NEOPLASMS; NEUTROPENIA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME;

EID: 77955827765     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Agaoglu L, Devecioglu O, Anak S, et al, (2001). Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother, 2, 281-7.
2. Baldwin CM, Lyseng-Williamson KA, Keam SJ (2008). Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs, 68, 803-38.
3. Erbey F, Bayram I, Yilmaz S, Tanyeli A (2009). Imipenem in the treatment of febrile neutropenic children. Asian Pac J Cancer Prev, 10, 921-4.
4. Hann L, Viscoli C, Paesmans M, Goya H, Glauser M, and IATCG of EORTC (1997). Comparison of outcome from febrile neutropenic episodes in children compared with adults: Results of four EORTC studies. Br J Haematol, 99, 580-8.
5. Hughes WT, Armstrong D, Bodey GP, et al, (2002). 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis, 34, 730-50.
6. Kutluk T, Kurne O, Akyüz C, et al, (2004). Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer, 42, 284-6.
7. Jones GR, Konslet GK, Pusek SN (1996). Infection risk factors in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol, 13, 217-29.
8. Müller J, Garami M, Constantin T, et al, (2005). Meropenem in the treatment of febrile neutropenic children. Pediatr Hematol Oncol, 22, 277-84.
9. Oguz A, Karadeniz C, Citak EC, Cil V, Eldes N (2006). Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. Pediatr Hematol Oncol, 23, 245-53.
10. Paulus S, Dobson S (2009). Febrile neutropenia in children with cancer. Adv Exp Med Biol, 634, 185-204.
11. Santolaya ME, Alvarez AM, Becker A, et al, (2001). Prospective multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, fever. J Clin Oncol, 19, 3415-21.
12. Vandercam B, Gerain J, Humblet Y, et al, (2000). Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol, 79, 152-7.
13. Yalci{dotless}n I (1998). Kanserli cocuklarda infeksiyon egilimi yaratan risk faktorleri. ANKEM Derg, 3, 350-2.
14. Yildirim I, Aytac S, Ceyhan M, et al, (2008). Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatr Hematol Oncol, 25, 291-9.